Results 301 to 310 of about 1,321,964 (375)

Longitudinal effect of HCV cure on markers of kidney disease. [PDF]

PLoS One
Cepeda J, Atta M, Zook K, Landry M, Maier P, Schwartz G, Lucas G.   +6 more
europepmc   +1 more source

Direct-acting antivirals (DAA) positively affect depression and cognitive function in patients with chronic hepatitis C. [PDF]

PLoS One
Pawłowski T, Radkowski M, Perlejewski K, Szymańska B, Berak H, Horban A, Laskus T.   +6 more
europepmc   +1 more source

Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations.

JAMA Netw Open
Jeong D, Wong S, Karim ME, Manges AR, Makuza JD, Velásquez García HA, Adu PA, Binka M, Yu A, Bartlett SR, Krajden M, Janjua NZ.   +11 more
europepmc   +1 more source

Chronic Inflammation: A Multidisciplinary Analysis of Shared Pathways in Autoimmune, Infectious, and Degenerative Diseases. [PDF]

Cureus
Yacine A, Zain Ali M, Alharbi AB, Qubayl Alanaz H, Saud Alrahili A, Alkhdairi AA.   +5 more
europepmc   +1 more source

Update on Chronic Hepatitis C [PDF]

Comprehensive Therapy, 2003
Strategies for the diagnosis and treatment of chronic hepatitis C continue to evolve. Liver biopsy is now used selectively rather than routinely, and the combination peginterferon plus ribavirin is the treatment of choice for the majority of patients.
Aijaz Ahmed, Emmet B. Keeffe
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Alcoholic Liver Disease and Hepatitis C Chronic Infection.

Reviews on recent clinical trials, 2016
Alcoholic and virus C hepatitis currently represent the main causes of chronic liver disease worldwide. Every year many people die and are subjected to complex hospitalization and medical assistance due to these pathologies.
A. Federico, M. Dallio, V. Ormando, L. Abenavoli, M. Masarone, M. Persico, C. Loguercio   +6 more
semanticscholar   +1 more source

Aminoadamantanes for chronic hepatitis C

Cochrane Database of Systematic Reviews, 2012
Around 3% of the world's population (approximately 160 million people) are chronically infected with hepatitis C virus. The proportion of infected people who develop clinical symptoms varies between 5% and 40%. Combination therapy with pegylated interferon-alpha plus ribavirin eradicates the virus from the blood six months after treatment (sustained ...
Lamers, M.H., Lamers, M.H., Broekman, M., Drenth, J.P.H., Drenth, J.P.H., Gluud, C.   +5 more
openaire   +4 more sources